1	
2	Masks Do No More Than Prevent Transmission:
3	Theory and Data Undermine the Variolation Hypothesis
4	
5	Katia Koelle ^{a,b,*} , Jack Lin ^a , Huisheng Zhu ^a , Rustom Antia ^{a,b} , Anice C. Lowen ^{b,c} , Daniel Weissman ^{a,d}
6	
7	^a Department of Biology, Emory University, Atlanta, GA
8	^b Emory Center of Excellence for Influenza Research and Response [CEIRR], Atlanta, GA
9	^c Department of Microbiology and Immunology, Emory University, Atlanta, GA
10	^d Department of Physics, Emory University, Atlanta, GA
11	
12	* corresponding author: <u>katia.koelle@emory.edu</u>
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24 25	
25	
20 27	
27 28	
20	

Abstract 29

Background. Masking serves an important role in reducing the transmission of respiratory 30 viruses, including SARS-CoV-2. During the COVID-19 pandemic, several perspective and review 31 articles have also argued that masking reduces the risk of developing severe disease by 32 33 reducing the inoculum dose received by the contact. This hypothesis - known as the 'variolation hypothesis' – has gained considerable traction since its development. 34

Methods. To assess the plausibility of this hypothesis, we develop a quantitative framework for 35 understanding the relationship between (i) inoculum dose and the risk of infection and (ii) 36 37 inoculum dose and the risk of developing severe disease. We parameterize the mathematical models underlying this framework with parameters relevant for SARS-CoV-2 to quantify these 38 relationships empirically and to gauge the range of inoculum doses in natural infections. We 39 40 then identify and analyze relevant experimental studies of SARS-CoV-2 to ascertain the extent

of empirical support for the proposed framework. 41

Results. Mathematical models, when simulated under parameter values appropriate for SARS-42 CoV-2, indicate that the risk of infection and the risk of developing severe disease both increase 43 44 with an increase in inoculum dose. However, the risk of infection increases from low to almost 45 certain infection at low inoculum doses (with <1000 initially infected cells). In contrast, the risk of developing severe disease is only sensitive to dose at very high inoculum levels, above 10⁶ 46 47 initially infected cells. By drawing on studies that have estimated transmission bottleneck sizes 48 of SARS-CoV-2, we find that inoculum doses are low in natural SARS-CoV-2 infections. As such, 49 reductions in inoculum dose through masking or greater social distancing are expected to reduce the risk of infection but not the risk of developing severe disease conditional on 50 51 infection. Our review of existing experimental studies support this finding.

52 Conclusions. We find that masking and other measures such as distancing that act to reduce 53 inoculum doses in natural infections are highly unlikely to impact the contact's risk of developing severe disease conditional on infection. However, in support of existing empirical 54 55 studies, we find that masking and other mitigation measures that reduce inoculum dose are expected to reduce the risk of infection with SARS-CoV-2. Our findings therefore undermine the 56 plausibility of the variolation hypothesis, underscoring the need to focus on other factors such 57 as comorbidities and host age for understanding the heterogeneity in disease outcomes for 58 59 SARS-CoV-2.

- 60
- 61
- 62
- 63

65 Introduction

The efficacy of masks in reducing infection risk has been shown in the context of SARS-CoV-2¹ 66 and for other respiratory viruses². Masks reduce the amount of virus shed in exhaled breath of 67 infected individuals³, reducing viral transmission potential. Although less effective than 'source 68 control^{1,2}, masking on the part of a contact also reduces infection risk. During the COVID-19 69 pandemic, an additional benefit of masking has been hypothesized: that masks can reduce 70 disease severity in individuals who become infected despite masking 4^{-6} . The initial articles 71 arguing that 'masks do more' than reduce viral transmission have been heavily cited^{4,5,7}, with 72 several follow-up articles that either express support of this hypothesis^{6,8} or are critical of it 73 based on the extent of evidence presented 9^{-11} or on findings from subsequent studies 12^{12} . 74

The potential for masks to lower the risk of disease has been termed the 'variolation hypothesis'⁴. The term variolation derives from a practice that was first documented in Asia in the 1500's to reduce an individual's risk of contracting smallpox. The practice involved inoculation of previously uninfected individuals using pulverized smallpox scabs. These challenged individuals only rarely developed severe disease in response to the inoculation but gained immunity to smallpox infection. A possible reason why variolation rarely led to severe disease is that the inoculum dose may have been low compared to a natural smallpox infection.

82 Here, we use mathematical modeling to develop a framework for assessing the plausibility of the variolation hypothesis as it pertains to respiratory viruses. We parameterize the models 83 with estimated parameter values for SARS-CoV-2 and test the predictions of this framework 84 using findings from existing experimental studies. Application of our framework to SARS-CoV-2 85 86 indicates that masking and other measures to reduce natural inoculum doses are highly unlikely 87 to impact the risk of developing disease in those individuals who become infected. However, our findings indicate that these measures are effective at reducing infection risk, consistent 88 with an existing body of empirical findings. 89

90 Methods

91 The relationship between inoculum dose and infection risk. The basic reproduction number R_0 92 in epidemiology quantifies the expected number of secondary cases resulting from a single infected case in an otherwise susceptible host population¹³. Given a value of R_0 and a measure 93 of the extent of transmission heterogeneity between individuals, the probability of an emerging 94 infectious agent establishing, rather than going stochastically extinct, can be calculated¹⁴. These 95 96 epidemiological calculations have analogies at the within-host level, where the within-host basic reproduction number ($R_{0, \text{ within}}$) quantifies the expected number of cells that will become 97 infected by virus progeny produced from a single infected cell early on in infection when target 98 cells are readily available and host immune responses have not yet developed. We thus use 99 mathematical expressions from the epidemiological literature to project how inoculum dose 100

64

101 impacts the probability of an individual becoming infected (Supplemental Material). We 102 parameterize the infection risk model based on existing SARS-CoV-2 literature estimates for $R_{0,}$ 103 $within^{15}$ and under a broad range of cell-to-cell heterogeneity levels. The range of heterogeneity 104 levels we consider span from no cell-to-cell heterogeneity to extreme levels of heterogeneity 105 with virus progeny from approximately 0.1% of infected cells being responsible for infecting 106 80% of the next generation of infected cells (Supplemental Material).

The relationship between inoculum dose and the risk of developing severe disease. Within-107 host models are commonly used to understand viral load and immune response dynamics¹⁶. To 108 109 project the relationship between inoculum dose and the risk of developing severe disease, we use an existing mathematical model for the viral and immune response dynamics during SARS-110 CoV-2 infection¹⁵. This model incorporates uninfected target cells, infected target cells, free 111 virus, and the innate immune response. We extend this model to further incorporate an 112 adaptive immune response, given the documented importance of the cellular immune response 113 in clearing SARS-CoV-2 infection and in modulating disease severity¹⁷. We further add an 114 equation to model tissue damage, which we ultimately use to quantify the extent of disease 115 severity. Model equations and parameterizations are provided in the Supplemental Material. 116 117 For any given parameterization (reflecting a given individual), we simulate the within-host 118 model starting with different values for the initial number of infected cells.

The inoculum dose in natural infections. To estimate the inoculum dose in natural SARS-CoV-2 119 infections, we used empirical estimates of the transmission bottleneck size of SARS-CoV- 2^{18-21} . 120 The transmission bottleneck size $N_{\rm b}$ is defined as the number of viral particles that establish 121 122 genetic lineages in an infected host. By contrast, inoculum dose is defined herein as the number of initially infected cells, which may be greater than $N_{\rm b}$. Under each considered inoculum dose, 123 we analytically calculated the probability of N_b being 1, 2, 3, etc. viral particles, conditional on 124 host infection (Supplemental Material). We used these probabilities to calculate the mean 125 bottleneck size under any given inoculum dose. We compared these mean bottleneck sizes 126 against the empirical mean estimate¹⁸ of $N_{\rm b}$ = 1.21 to determine a plausible range of natural 127 inoculum doses. 128

129 Results

The expected relationship between inoculum dose and infection risk. To parameterize the 130 infection risk model, we consider three values of R_{0, within}: 7.4, 2.6, and 14.9, corresponding to 131 132 the mean, low, and high estimates derived from a within-host viral dynamic model that was fit to viral load data from 17 infected individuals¹⁵. With $R_{0, \text{ within}} = 7.4$ and in the absence of cell-to-133 cell heterogeneity ($k = \infty$), the risk of infection was close to 100% in the case of the inoculum 134 dose being one or more initially infected cells (Figure 1). At any given inoculum dose, the risk of 135 136 infection was lower at higher levels of cell-to-cell heterogeneity. However, even at extreme levels of cell-to-cell heterogeneity, infection risk saturated at 100% with inoculum doses of 137 approximately 100-1000 initially infected cells. The overall patterns of infection risk were 138

similar for a higher $R_{0, \text{ within}}$ (of 14.9) and a lower $R_{0, \text{ within}}$ (of 2.6). These results indicate that, for viral infections with high within-host basic reproduction numbers ($R_{0, \text{ within}}$ >2), infection risk increases rapidly with increases in inoculum dose only over a range of low viral inoculum doses; at high inoculum doses, infection is already ensured.

The expected relationship between inoculum dose and risk of developing severe disease. 143 Simulation of the within-host viral dynamic model, parameterized with baseline values and 144 starting with an inoculum dose of 10 initially infected cells, recapitulated key features of SARS-145 CoV-2 within-host dynamics. Viral load increased over a period of approximately 6 days, peaked 146 at approximately 10⁷ genome equivalents per ml, and then declined to undetectable levels 147 within the following ~8 days (Figure 2A). Tissue damage, driven by proinflammatory cytokines 148 and T-cell-induced pathology, increased as viral load increased, peaked at around the same 149 150 time as viral load, and then declined (Figure 2B). Only approximately 10% of target cells were 151 killed over the course of the infection, with viral regulation resulting primarily from the innate 152 immune response initially, followed by the cellular immune response (Supplemental Material).

Increasing the inoculum dose by three orders of magnitude (10⁴ initially infected cells), 153 decreased the time between infection and peak viral load (Figure 2A), and similarly sped up the 154 dynamics of the other variables (Figure 2B; Supplemental Material). Despite these kinetic 155 differences, the dynamics are quantitatively similar to those with a low inoculum dose of 10 156 157 initially infected cells such that the risk of developing severe disease was similar at these two doses. However, at an even higher inoculum dose of 1.6x10⁷ initially infected cells 158 159 (corresponding to \sim 20% of the total number of target cells), the within-host dynamics are substantially different from those at the two lower doses: viral titers peak at higher levels 160 161 (Figure 2A), fewer target cells remain (Supplemental Material), and tissue damage is more substantial (Figure 2B), resulting in a higher risk of developing severe disease (Figure 2C). 162

To gauge the point at which the risk of developing severe disease increases, we simulated the within-host model across a wide range of inoculum doses, calculating the risk at each inoculum dose (**Figure 2C**). In **Figure 2D**, we plot this risk in terms of fold change relative to an infection starting from 10 initially infected cells. This figure shows that across >6 orders of magnitude difference in inoculum dose, from a single initially infected cell to ~10⁶ initially infected cells, the risk of developing severe disease is insensitive to dose; only at extremely high doses does the risk of developing severe disease increase with an increase in dose.

170 To examine interindividual variation in the risk of developing severe disease, we simulated the within-host model 10 times, with parameter values drawn from distributions with mean values 171 172 given by the baseline parameterized model (Supplemental Material). Simulated viral dynamics 173 and tissue damage dynamics were variable between these 10 simulations (Supplemental Material), resulting in highly variable risks of developing severe disease across individuals at a 174 given inoculum dose (Figure 2C). However, plotting the risk for each of these 10 individuals 175 176 relative to the risk under the assumption of 10 initially infected cells again indicates that the risk of developing severe disease is insensitive to the inoculum dose until doses approach very 177 178 high levels (Figure 2D).

Our finding that the risk of developing severe disease is insensitive to dose across a broad range 179 of inoculum doses, ranging from a single initially infected cell to $\sim 10^6$ initially infected cells ($\sim 1\%$ 180 of initially available target cells), can be generally understood in the context of how host 181 immunity responds to viral infection. At any inoculum dose, host immunity develops in 182 183 response to viral infection. When inoculum doses are not extremely large, this immune 184 response can effectively regulate viral dynamics. At extremely large inoculum doses, however, the host immune response does not have the ability to quickly regulate within-host viral 185 dynamics, and as such, the number of infected cells is significantly higher. A higher number of 186 187 infected cells results in higher interferon levels, which act to control the viral infection but also lead to higher levels of interferon-induced pathology. Simplifications of the within-host model 188 we use here demonstrate this point (Supplemental Material). 189

Inference of inoculum dose in natural infections. Figure 3A shows the expected transmission 190 bottleneck size under a range of inoculum doses, under the same set of values of R_{0, within} and 191 cell-to-cell heterogeneity levels considered in Figure 1. Even at an extreme level of cell-to-cell 192 heterogeneity (k = 0.001), the inoculum dose that yields an expected transmission bottleneck 193 194 size of 1.21 does not exceed 124 initially infected cells. Even if transmission bottleneck sizes 195 were an order of magnitude higher (~10 viral particles), the inoculum dose would not exceed 196 $^{\sim}$ 3000 initially infected cells. These results indicate that the inoculum dose in natural SARS-CoV-2 infections is very low. In this range of inoculum doses, reductions in dose would be expected 197 to decrease the risk of infection but not have an effect on the risk of developing severe disease. 198 In Figure 3B, we show the distribution of transmission bottleneck sizes that has been previously 199 inferred from empirical studies¹⁸. Figures 3C-G show that expected distributions of transmission 200 bottleneck sizes under different cell-to-cell heterogeneity levels, parameterized with inoculum 201 doses that yield mean $N_{\rm b}$ estimates that are closest to the value of 1.21, quantitatively 202 203 reproduce the inferred empirical distribution.

Analysis of experimental challenge studies. Our modeling provides two predictions relevant to the variolation hypothesis: (i) in the range of low inoculum doses, infection risk decreases with a decrease in inoculum dose, but the risk of developing severe disease (conditional on infection) is not substantially impacted; and (ii) in the range of very high inoculum doses, the risk of developing severe disease decreases with a decrease in inoculum dose, but infection risk is not impacted (individuals will become infected despite decreases in dose).

210 To test these predictions, we turn to experimental SARS-CoV-2 challenge studies. The most 211 relevant of these studies are ones that measure disease outcomes in contact (sentinel) animals, across experimental designs that have the potential to modulate infection dose. In these 212 213 experiments, we expect that inoculum doses of sentinel animals are of similar orders of magnitude to those of humans experiencing natural infection. We found two relevant 214 studies^{22,23}. The first study²² assessed the efficacy of masks for reducing transmission risk using 215 a Syrian hamster model. They found that masking significantly reduced the risk of infection of 216 217 sentinel hamsters from 10/15 (66.7%) to 6/24 (25.0%) (p = 0.018; Fisher exact test). The study

218 also reported that the sentinel hamsters in the masked arms of the experiments had lower clinical severity scores and milder histopathological changes, consistent with the variolation 219 220 hypothesis. However, the authors did not condition on infection and uninfected sentinel hamsters exhibited no clinical symptoms. Inclusion of uninfected sentinel hamsters therefore 221 222 would bias clinical severity scores to be lower in the masked arms of the experiment relative to the unmasked arm of the experiment. We reanalyzed their data (Supplemental Material) and 223 did not find a statistically significant difference in the clinical severity scores of infected sentinel 224 hamsters between the masked and unmasked treatment groups (p = 0.07 for 5 dpi; p = 0.27 for 225 226 7 dpi; Mann-Whitney U test; Supplemental Material). The data from this study therefore indicate that masking reduces infection risk but do not demonstrate significant impact of 227 masking on disease outcome during transmission from an index to a contact individual. 228

A second study²³ examined SARS-CoV-2 transmission efficiency from inoculated to contact 229 animals, also using the Syrian hamster model. The study found that transmission efficiency was 230 high in exposures that lasted one or more hours when the index animals were inoculated with 231 1x10⁴ PFU of virus. In a follow-up experiment that examined transmission efficiency at different 232 233 points in time following index inoculation, the authors allowed contact between sentinel and 234 index cases for one to two hours, at different time periods post-inoculation. Transmission was 235 found to be most efficient when viral load in the inoculated animal was high (17 h to 2 d post-236 inoculation), consistent with the risk of infection of a contact animal depending on dose when 237 doses are low. However, infected contact animals across the different exposure time blocks did not exhibit statistically significant differences in infection severity as measured by weight loss 238 239 (all p-values > 0.05; two-sample t-test; Supplemental Material), even though one would expect 240 exposure during high viral load of the index case to increase inoculum dose. However, infected 241 contact animals did exhibit a statistically significant (p = 0.004; two-sample t-test), yet small, 242 amount of weight loss relative to their uninfected counterparts. These results are consistent with other experimental transmission studies on Syrian hamsters that found either small or 243 insignificant amounts of weight loss in infected contact animals^{24,25}. 244

Another set of studies that has the potential to give insight into the effect of dose on disease 245 246 outcomes are those that modulate inoculum dose across a wide range of values in experimentally challenged donor animals. One such study²⁶ assessed the effect of SARS-CoV-2 247 inoculum dose on seroconversion and fever development in a non-human primate model. 248 249 Positive relationships were observed between deposited dose and seroconversion (an indicator of infection, albeit an imperfect one; Figure 4A) and also between deposited dose and fever 250 development (Figure 4B). A similar effect was maintained when we reanalyzed the data by 251 estimating the relationship between deposited dose and fever development, conditional on 252 253 seroconversion (Figure 4B; Supplemental Material). As already remarked on in the original data analysis²⁶, the median infectious dose that resulted in fever development was significantly 254 higher than the median infectious dose that resulted in seroconversion (256 TCID50 vs. 52 255 TCID50), a result that was maintained when fever development was conditioned on 256 seroconversion (Figure 4). We further fit an alternative model to these data to allow for a non-257

258 zero probability of developing fever at low inoculum doses, conditional on infection. The 259 extended model, which was statistically preferred over the original logistic model, predicted an 260 even higher inoculum dose for the median infectious dose that resulted in fever development 261 (460 TCID50; Figure 4B). This analysis therefore provides empirical support for the modeling 262 results presented above: at low inoculum doses, an increase in dose increases the risk of 263 infection but not the risk of developing disease.

Another SARS-CoV-2 experimental challenge study examined disease outcomes at more than one dose²⁷. However, this study considered dose ranges that ranged from high to very high (referred to as "low" and "high" dose, respectively, in their study) with all challenged animals becoming infected. At these dose levels, we expect that there might be a positive relationship between dose and disease severity. The findings from this study meet this expectation²⁷ but do not provide support in favor of the variolation hypothesis because the inoculum doses used in this study lie outside the range of natural ones.

271 Discussion

Here, we have used mathematical models to study the relationships between inoculum dose 272 and the risks of infection and of developing severe disease. Based on parameterizations of 273 these models for SARS-CoV-2, we argue that decreases in the inoculum dose, for example 274 through masking, will only result in lower probabilities of infection when the natural inoculum 275 276 dose is low. We further argue that decreases in the inoculum dose will only result in less severe 277 disease when the natural inoculum dose is high. Our comparison of expected and empirical estimates of transmission bottleneck size indicates that natural inoculum doses are very low, 278 such that masking (as documented¹) is expected to reduce transmission potential. However, 279 280 this means that masking is highly unlikely to reduce the risk of developing severe disease, conditional on infection. Our results thereby undermine the plausibility of the variolation 281 282 hypothesis. Our results are consistent with experimental challenge studies, which have not found a significant difference in disease outcomes in contact animals infected with different but 283 small inoculum doses; however, disease outcomes in index animals that are inoculated with 284 high doses have been shown to differ, with higher doses resulting in more severe disease²⁷. 285

286 We restricted our analyses to ones involving experimental challenge studies. While there are observational studies that have argued against the variolation hypothesis¹², we feel that these 287 studies offer an absence of evidence rather than evidence of absence, owing to uncertainty in 288 289 the data. Other studies have been invoked to instead support the variolation hypothesis. For example, it has been argued that the higher asymptomatic rate on board of the Greg Mortimer 290 ship destined for Antarctica (81%)²⁸ relative to the asymptomatic rate on board of the Diamond 291 Princess (17.9%)²⁹ was due to masking on the Greg Mortimer⁵. However, alternative 292 explanations, such as differences in the age distribution of the passengers or differences in the 293 294 SARS-CoV-2 tests used, were not considered.

An alternative hypothesis to consider is that masks may modulate disease severity not by 295 decreasing inoculum dose but by modulating the mode of transmission³⁰. A viral inoculum 296 delivered in larger droplets, such as those that comprise a spray, would become trapped in the 297 298 nasal passages and upper airways. Conversely, small aerosolized particles can penetrate the 299 lower lungs, where infection is more likely to result in severe symptoms. While masks that 300 create a seal around the nose and mouth can limit inhalation of aerosols, most are more effective at limiting transfer of a droplet spray. Thus, while masking is expected to lower the 301 overall number of infections, it could increase the proportion of cases resulting from inhalation 302 303 directly to the lower respiratory tract. For this reason, we suggest that an effect of masking on modes of transmission is not consistent with the variolation hypothesis. 304

Our finding that masking and measures of social distancing that reduce inoculum dose are unlikely to do more than protect against infection has relevance to other respiratory viruses such as influenza, which is also characterized by a small transmission bottleneck size³¹. Masking would be expected to reduce incidence of infection, helping to limit the impact of influenza at a population level. To reduce disease in those infected, whether it be with influenza, SARS-CoV-2, or another respiratory virus characterized by a small inoculum dose, vaccination likely remains

- 311 the most effective countermeasure 32,33 .
- 312

313 Acknowledgments

314 We thank Dr. Jasper Chan and Dr. Kwok-Yung Yuen for providing their study's individual-level clinical 315 severity score data upon request. We further thank Ketaki Ganti and Lucas Ferreri for providing 316 individual-level weight data from the Ganti et. al. study, and Narendra Dixit for helpful conversations 317 about their SARS-CoV-2 within-host model. This work was funded by NIH/NIAID Centers of Excellence in 318 Influenza Research and Response (CEIRR), contract number 75N93021C00017 to KK, RA and ACL. DW was supported by the Simons Foundation via a Mathematical Modeling of Living Systems Investigator 319 320 award, the Sloan Foundation via a Research Fellowship, the NSF via CAREER award PHY-2146260, the 321 Gordon and Betty Moore Foundation grant 2919.02, and the Kavli Institute for Theoretical Physics by 322 NSF grant PHY-1748958.

323

324 References

- Howard J, Huang A, Li Z, *et al.* An evidence review of face masks against COVID-19. *Proc Natl Acad Sci USA* 2021; **118**: e2014564118.
- Cowling BJ, Zhou Y, Ip DKM, Leung GM, Aiello AE. Face masks to prevent transmission of influenza
 virus: a systematic review. *Epidemiol Infect* 2010; **138**: 449–56.
- 329 3 Leung NHL, Chu DKW, Shiu EYC, *et al.* Respiratory virus shedding in exhaled breath and efficacy of
 face masks. *Nat Med* 2020; **26**: 676–80.

- Gandhi M, Rutherford GW. Facial Masking for Covid-19 Potential for "Variolation" as We Await a
 Vaccine. *N Engl J Med* 2020; **383**: e101.
- Gandhi M, Beyrer C, Goosby E. Masks Do More Than Protect Others During COVID-19: Reducing the
 Inoculum of SARS-CoV-2 to Protect the Wearer. *J GEN INTERN MED* 2020; published online July 31.
 DOI:10.1007/s11606-020-06067-8.
- Sehrawat S, Rouse BT. COVID-19: disease, or no disease? that is the question. It's the dose stupid!
 Microbes and Infection 2021; 23: 104779.
- Spinelli MA, Glidden DV, Gennatas ED, *et al.* Importance of non-pharmaceutical interventions in
 lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially
 disease severity. *The Lancet Infectious Diseases* 2021; **21**: e296–301.
- 8 Van Damme W, Dahake R, van de Pas R, Vanham G, Assefa Y. COVID-19: Does the infectious inoculum
 dose-response relationship contribute to understanding heterogeneity in disease severity and
 transmission dynamics? *Medical Hypotheses* 2021; **146**: 110431.
- Trunfio M, Calcagno A, Bonora S, Di Perri G. Lowering SARS-CoV-2 viral load might affect transmission
 but not disease severity in secondary cases. *The Lancet Infectious Diseases* 2021; 21: 914–5.
- 10 Escandón K, Rasmussen AL, Bogoch II, *et al.* COVID-19 false dichotomies and a comprehensive review
 of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask
 wearing, and reinfection. *BMC Infect Dis* 2021; **21**: 710.
- 11 Facial Masking for Covid-19. *N Engl J Med* 2020; **383**: 2092–4.
- 12 Trunfio M, Longo BM, Alladio F, *et al.* On the SARS-CoV-2 "Variolation Hypothesis": No Association
 Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. *Front Microbiol* 2021;
 12: 646679.
- 13 Anderson RM, May RM. Infectious diseases of humans: dynamics and control, Reprinted. Oxford:
 Oxford Univ. Press, 2010.
- 14 Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual variation
 on disease emergence. *Nature* 2005; **438**: 355–9.
- 15 Ke R, Zitzmann C, Ho DD, Ribeiro RM, Perelson AS. In vivo kinetics of SARS-CoV-2 infection and its
 relationship with a person's infectiousness. *Proc Natl Acad Sci USA* 2021; **118**: e2111477118.
- 16 Perelson AS. Modelling viral and immune system dynamics. *Nat Rev Immunol* 2002; **2**: 28–36.
- 17 Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol* 2022; **23**: 186–93.

18 Martin MA, Koelle K. Comment on "Genomic epidemiology of superspreading events in Austria
 reveals mutational dynamics and transmission properties of SARS-CoV-2". Sci Transl Med 2021; 13:
 eabh1803.

- 364 19 Lythgoe KA, Hall M, Ferretti L, *et al.* SARS-CoV-2 within-host diversity and transmission. *Science* 2021;
 372: eabg0821.
- 20 Braun KM, Moreno GK, Halfmann PJ, *et al.* Transmission of SARS-CoV-2 in domestic cats imposes a
 narrow bottleneck. *PLoS Pathog* 2021; **17**: e1009373.
- 368 21 Braun K, Moreno G, Wagner C, *et al.* Limited within-host diversity and tight transmission bottlenecks
 369 limit SARS-CoV-2 evolution in acutely infected individuals. Evolutionary Biology, 2021
 370 DOI:10.1101/2021.04.30.440988.
- 22 Chan JF-W, Yuan S, Zhang AJ, *et al.* Surgical Mask Partition Reduces the Risk of Noncontact
 Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19). *Clinical Infectious Diseases* 2020; **71**: 2139–49.
- 374 23 Ganti K, Ferreri LM, Lee C-Y, *et al.* Timing of exposure is critical in a highly sensitive model of SARS 375 CoV-2 transmission. *PLoS Pathog* 2022; **18**: e1010181.
- 24 Port JR, Yinda CK, Avanzato VA, *et al.* Increased small particle aerosol transmission of B.1.1.7
 compared with SARS-CoV-2 lineage A in vivo. *Nat Microbiol* 2022; **7**: 213–23.
- 25 Port JR, Yinda CK, Owusu IO, *et al.* SARS-CoV-2 disease severity and transmission efficiency is
 increased for airborne compared to fomite exposure in Syrian hamsters. *Nat Commun* 2021; **12**:
 4985.
- 26 Dabisch PA, Biryukov J, Beck K, *et al.* Seroconversion and fever are dose-dependent in a nonhuman
 primate model of inhalational COVID-19. *PLoS Pathog* 2021; **17**: e1009865.
- 27 Imai M, Iwatsuki-Horimoto K, Hatta M, *et al.* Syrian hamsters as a small animal model for SARS-CoV-2
 infection and countermeasure development. *Proc Natl Acad Sci USA* 2020; : 202009799.
- 28 lng AJ, Cocks C, Green JP. COVID-19: in the footsteps of Ernest Shackleton. *Thorax* 2020; **75**: 693–4.
- 29 Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of
 coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama,
- 388 Japan, 2020. *Eurosurveillance* 2020; **25**. DOI:10.2807/1560-7917.ES.2020.25.10.2000180.
- 389 30 Prather KA, Wang CC, Schooley RT. Reducing transmission of SARS-CoV-2. *Science* 2020; **368**: 1422–4.
- 31 McCrone JT, Woods RJ, Martin ET, Malosh RE, Monto AS, Lauring AS. Stochastic processes constrain
 the within and between host evolution of influenza virus. *eLife* 2018; **7**. DOI:10.7554/eLife.35962.
- 32 Gross PA. The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the
 Literature. Ann Intern Med 1995; 123: 518.
- 33 Feikin DR, Higdon MM, Abu-Raddad LJ, *et al.* Duration of effectiveness of vaccines against SARS-CoV 2 infection and COVID-19 disease: results of a systematic review and meta-regression. *The Lancet* 2022; **399**: 924–44.
- 397

398

399

400 Figures

401

Figure 1. The relationship between inoculum dose and the risk of infection for SARS-CoV-2. Inoculum dose is defined here as the initial number of infected cells. Relationships are shown for $R_{0, \text{ within}} = 7.4$ (solid lines), $R_{0, \text{ within}} = 2.6$ (dashed lines), and $R_{0, \text{ within}} = 14.9$ (dotted lines). Line colors denote the extent of cell-to-cell heterogeneity: overdispersion parameter $k = \infty$ (blue; no cell-to-cell heterogeneity), k = 1(brown), k = 0.1 (yellow), k = 0.01 (purple), and k = 0.001 (green; extreme level of cell-to-cell heterogeneity). These k values correspond to approximately 65%, 40%, 10%, 1%, and 0.1% of the most infectious cells giving rise to 80% of secondary infected cells, respectively.

409 Figure 2. The relationship between inoculum dose and the risk of developing severe disease for SARS-410 CoV-2. (A) Viral dynamics, and (B) corresponding tissue damage dynamics, simulated using the withinhost model parameterized with baseline values, for three inoculum doses: 10 (yellow), 10⁴ (orange), and 411 1.6x10⁷ (red) initially infected cells. (C) Disease severity of infection over a broad range of inoculum 412 413 doses. Solid black line shows results for the within-host model parameterized at baseline values. Dashed 414 gray lines show results for 10 individuals, with parameters sampled from the provided distributions 415 detailed in the Supplemental Material. (D) Disease severity, for the baseline model parameterization 416 (black) and 10 individuals (dashed gray), as in (C), in terms of fold change. Fold change is relative to the 417 disease severity level resulting from infection starting with 10 infected cells. Vertical yellow, orange, and 418 red lines in panels (C) and (D) show the inoculum doses used in the simulations shown in (A) and (B).

419 Figure 3. Inference of the natural inoculum dose. (A) The relationship between inoculum dose and 420 mean bottleneck size. Lines show the expected relationship under a given within-host basic 421 reproduction number and a given level of cell-to-cell heterogeneity. As in Figure 1, dashed, solid, and dotted lines correspond to R_{0, within} values of 2.6, 7.4, and 14.9, respectively, and line colors denote the 422 423 extent of cell-to-cell heterogeneity. Gray line shows the mean transmission bottleneck size of 1.21. (B) Inferred distribution of transmission bottleneck sizes, reproduced from ¹⁸, showing the number of viral 424 425 particles that establish genetic lineages in an infected individual and their corresponding probabilities. (C-G) Expected distribution of transmission bottleneck sizes for models parameterized with an R_{0, within} of 426 427 7.4 and inoculum doses that yield a mean bottleneck size that is closest to the previously inferred value 428 of 1.21. Panels differ in their cell-to-cell heterogeneity levels. These doses correspond to 1 (C; k = lnf), 1 (D; k = 1), 2 (E; k = 0.1), 13 (F; k = 0.01), and 124 (G; k = 0.001) initally infected cells. 429

430 Figure 4. The relationship between inoculum dose, seroconversion, and fever development. Data derive from a non-human primate SARS-CoV-2 challenge study²⁶, with inoculum doses ranging from low 431 432 to high. Deposited doses are calculated from inoculum doses, incorporating deposition fraction 433 estimates and accounting for variation in respiratory geometry. (A) The relationship between deposited 434 dose and infection risk. Individual-level data points are shown as open black circles. Solid black line 435 shows the fit of a logistic regression model. The median dose that results in seroconversion is 52 TCID50, as previously reported²⁶. (B) The relationship between deposited dose and the probability of developing 436 437 fever. Individual-level data points are shown as open black circles. Red asterisks within a subset of these data points indicate the subset of individuals that seroconverted. Solid black line shows the fit of a logistic regression model to all individual-level data points. Red solid line shows the fit of a logistic regression model to the subset of individuals that seroconverted. The median dose that results in fever development is is approximately 256 TCID50 for both models. The red dashed line shows the fit of the alternative logistic model to the subset of animals that seroconverted.

443







